 NEW YORK, Aug. 5, 2021 PRNewswire -- Synaptogenix, Inc. Nasdaq: SNPX, an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that it signed a memorandum of understanding MOU with the Nemours A.I. DuPont Hospital for Children, an internationally recognized leader in the comprehensive care of childhood diseases, with the intention of initiating a trial to treat Fragile X with Bryostatin. 